Introduction {#s1}
============

Recent reports ([@bib6]; [@bib17]) described the existence of a network of true lymphatic vessels within the mammalian dura mater that runs alongside blood vessels, notably the superior sagittal and transverse sinuses. The dural lymphatic vessels display typical immunohistochemical markers that identify lymphatic vessels elsewhere in the body. They provide an alternate conduit for drainage of immune cells and cerebrospinal fluid (CSF) from the brain, beyond previously described pathways of flow: via arachnoid granulations into the dural venous sinuses, and via the cribriform plate into the ethmoid region ([@bib31]). Although early reports, based on injections of India ink into the cisterna magna of the rat, suggested that the dural pathway accounts for only a minority of the drainage ([@bib11]), the more recent studies ([@bib6]; [@bib17]), which are based on injections of fluorescent tracers and in vivo microscopy, indicate that the dural system may be substantially more important for drainage of macromolecules and immune cells than previously realized.

Whether a similar network of dural lymphatics is present in primates remains unknown. Moreover, noninvasive visualization of the dural lymphatics -- a necessary first step to understanding their normal physiology and potential aberrations in neurological diseases -- has not been reported. We therefore verified pathologically the existence of a dural lymphatic network in human and nonhuman primates (common marmoset monkeys) and evaluated two magnetic resonance imaging (MRI) techniques that might enable its visualization in vivo. First, the T2-weighted fluid-attenuation inversion recovery (T2-FLAIR) pulse sequence, which is the clinical standard for detecting lesions within the brain parenchyma, is highly sensitive to the presence of gadolinium-based contrast agents in the CSF ([@bib20]; [@bib23]; [@bib2]). Second, 'black-blood' imaging sequences, which are typically used for measurement of vascular wall thickness or detection of atherosclerotic plaque, are tuned to darken the contents of blood vessels (even when they contain a gadolinium-based contrast agent), but in the process the images may highlight vessels with other contents and flow properties ([@bib21]). For comparison, we also acquired a postcontrast T1-weighted Magnetization Prepared Rapid Acquisition of Gradient Echoes (MPRAGE) MRI sequence, which is widely implemented for structural brain imaging and depicts avid enhancement of dura mater and blood vessels, but which would not be expected to discriminate lymphatic vessels.

Results and discussion {#s2}
======================

Cerebral blood vessels have a highly regulated blood-brain barrier, protecting the neuropil from many contents of the circulating blood. Under physiological conditions, the blood-brain barrier prevents gadolinium-based chelates in standard clinical use from passing into the Virchow-Robin perivascular spaces and parenchyma, so that these structures do not enhance on MRI. On the other hand, dural blood vessels lack a blood-meningeal barrier, enabling leakage of circulating fluids and small substances, including gadolinium-based compounds. This explains the thin, though often incomplete, dural enhancement that is seen on conventional T1-weighted MRI scans under physiological conditions ([Figure 1](#fig1){ref-type="fig"}), as well as its abnormal diffuse or localized thickening in a variety of pathological conditions ([@bib28]; [@bib4]). Using high-resolution (in-plane resolution 270 × 270 μm or finer) T2-FLAIR and T1-weighted black-blood MRI images, obtained after the intravenous injection of standard FDA-approved contrast material (gadobutrol), we were able to visualize the collection of interstitial gadolinium within dural lymphatic vessels (maximum apparent diameter \~1 mm) in 5/5 human healthy volunteers and 3/3 common marmoset monkeys ([Figure 1](#fig1){ref-type="fig"}). Our results suggest that in the dura, similar to many other organs throughout the body, small intravascular molecules extravasate into the interstitium and then, under a hydrostatic pressure gradient, collect into lymphatic capillaries through a loose lymphatic endothelium ([@bib27]).

![MRI-visualization of dural lymphatic vessels in human and nonhuman primates.\
In both species, conventional post-gadobutrol coronal T1-weighted MRI is unable to discriminate lymphatic vessels due to diffuse physiological enhancement of the dura (arrows) and blood vessels, including the superior sagittal sinus and straight sinus (arrows). On post-gadobutrol coronal T2-FLAIR and subtraction images, the dura does not enhance, and lymphatic vessels (red arrows), running alongside the venous dural sinuses and within the falx cerebri, can be appreciated. Numbers refer to minutes after the intravenous administration of gadobutrol.](elife-29738-fig1){#fig1}

To further test this hypothesis, meningeal lymphatics were also assessed using a second gadolinium-based contrast agent, gadofosveset, a blood-pool contrast agent suitable for angiography ([@bib15]). Gadofosveset binds reversibly to serum albumin, increasing its molecular weight from 0.9 to 67 kDa. Under physiological conditions, albumin has a low transcapillary exchange rate into the interstitial compartment, estimated to be on the order of 5% per hour, which explains the propensity of gadofosveset to remain within blood vessels ([@bib26]). In both species, gadofosveset did not reveal dural lymphatics, especially on T1-black blood images ([Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). As expected, on T1-weighted MPRAGE images, gadofosveset provided superior intravascular enhancement, in both meningeal and parenchymal blood vessels, compared to gadobutrol ([Figure 2](#fig2){ref-type="fig"}).

![Gadobutrol vs. gadofosveset in MRI-visualization of dural lymphatic vessels.\
Coronal T1-weighted black-blood images were acquired after intravenous injection of two different gadolinium-based contrast agents (31 min after gadobutrol and 42 min after gadofosveset), during two MRI sessions separated by one week. Dural lymphatics (red arrows in magnified view boxes) were better discerned using gadobutrol (standard MRI contrast agent, which readily enters the dura) compared to gadofosveset (serum albumin-binding contrast agent, which remains largely intravascular) and were localized around dural sinuses, middle meningeal artery, and cribriform plate (white arrows). Notably, the choroid plexus (white arrows) enhanced less with gadofosveset than gadobutrol, whereas meningeal and parenchymal blood vessels (both veins and arteries) did not enhance with any contrast agent and appeared black. On conventional T1-weighted MPRAGE images, meningeal and parenchymal blood vessels enhanced with both contrast agents, more clearly with gadofosveset.](elife-29738-fig2){#fig2}

On 3D-rendering of subtraction MRI images ([Videos 1](#video1){ref-type="video"}--[2](#video2){ref-type="video"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), dural lymphatics are seen running parallel to the dural venous sinuses, especially the superior sagittal and straight sinuses, and alongside branches of the middle meningeal artery. The topography of the meningeal lymphatics fits with the previously described network in rodents as well as our neuropathological data ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). It is worth noting that the lymphatics visualized by MRI are large slow-flow lymphatic ducts, whereas blind-ending and small lymphatic capillaries, clearly seen by histopathology ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), are unlikely to be revealed by MRI. The induction of experimental autoimmune encephalomyelitis (EAE) did not affect detection of dural lymphatic vessel in either of the two animals that we tested (not shown).

![Histopathology of human dural lymphatic vessels.\
(**A--B**) Whole-mount and coronal views of the human dura mater before sampling for histological analysis. The dotted line in A shows where the superior sagittal sinus runs within the dural layers. (**C**) Coronal section of human dura stained with H and E to highlight anatomical features of interest, including the falx cerebri and the dural venous sinus. Note the distortion of the dura after paraffin embedding in comparison to B. (**D, F, G**) Within the dura mater, lymphatic and blood vessels can be differentiated using double immunostaining for PROX1 (a transcription factor involved in lymphangiogenesis, nuclear staining) and CD31 (a vascular endothelial cell marker). (**E, H--K**) Similarly, lymphatic and blood vessels can be differentiated using immunohistochemical (**E, H, I**) and immunofluorescent (**J, K**) double staining for podoplanin (D2-40, endothelial membrane staining) and CD31. Red blood cells are seen within blood vessels, but not within lymphatic vessels. Insets (**F--I**) were rotated relative to the original figures in D and E. *Abbreviations:* H and E: hematoxylin and eosin; LV: lymphatic vessels; BV: blood vessels.\
10.7554/eLife.29738.010Figure 3---source data 1.Table of human tissue sampling.](elife-29738-fig3){#fig3}

![Histopathology of dural lymphatic vessels in common marmosets.\
MRI-histopathological correlation in a 4.4-year-old marmoset (**A--F**). (**A, B**) Postcontrast coronal T2-FLAIR showing three enhancing lymphatic vessels within the dura, and corresponding H and E section for anatomical reference (area of interest in the box). (**C-F**) Three clusters of cells (circles), surrounding the SSS and positive for lymphatic endothelial cell markers, correspond to the three enhancing areas seen on MRI (**A**). LYVE-1 is a lymphatic endothelial cell marker (membrane staining), PROX1 and COUP-TFII are transcription factors involved in lymphangiogenesis (nuclear staining), and CCL21 is a chemokine implicated in lymphatic transmigration. Higher magnifications are shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. 10.3-year-old marmoset (**G-I**). (**G**) H and E coronal section showing the brain parenchyma, meninges, and area of interest for lymphatics for anatomical reference (box). This animal did not recover after undergoing general anesthesia for blood tuberculosis testing, and at necropsy a stroke was identified in one hemisphere (asterisk). (H-I) Lymphatic (circles) and blood vessels were differentiated using double staining for podoplanin (D2-40, endothelial membrane staining) and vascular endothelial cell marker (CD31), respectively. 3.7-year-old marmoset (**J-L**). (**J**) Whole-mount of the marmoset dura, including the SSS. The high level of vascularization of the dura can be appreciated. The arrow indicates the area shown in K and L. (**K, L**) Double staining for podoplanin D2-40 for lymphatics, and CD31 for vascular endothelial cells, show the presence of a linear vascular structure parallel to the SSS, positive for podoplanin D2-40 but not CD31. The SSS is positive for both markers, probably because of antibody entrapment during immunofluorescence staining of the whole-mount dura. Abbreviations: H and E: hematoxylin and eosin; LV: lymphatic vessels; SSS: superior sagittal sinus.\
10.7554/eLife.29738.013Figure 4---source data 1.Table of marmoset tissue sampling.](elife-29738-fig4){#fig4}

###### 3D-rendering of dural lymphatics (green) in a 47 year old woman from skull-stripped subtraction T1-black-blood images (horizontal view, 180 degrees, 7 frames/minute).

10.7554/eLife.29738.014

###### 3D-rendering of dural lymphatics (green) in a 6.7-year-old common marmoset from skull-stripped subtraction T2-FLAIR images (horizontal view, 180 degrees, 7 frames/minute).

10.7554/eLife.29738.015

To support our in vivo imaging results, we further investigated the existence and topography of lymphatics in coronal and longitudinal sections of human and marmoset dura mater. To accomplish this, we tested a variety of putative lymphatic endothelial markers and found that selective double immunostaining for D2-40 podoplanin/CD31 and for PROX1/CD31 was the most effective strategy in discriminating lymphatic *vs.* venous blood vessels in dura samples -- a challenging task since lymphatics sprout from transdifferentiation of venous endothelium ([@bib24]; [@bib33]; [@bib29]; [@bib5]; [@bib18]) and persistently share some endothelial markers. A branched network of lymphatics was clearly seen within the dura mater. On D2-40 podoplanin/CD31 double staining, we identified a total of 93 human dural lymphatics; most were collapsed, explaining the large range of maximum transverse diameters (range = 7--842 μm, mean = 125 μm, standard deviation = 161 μm). The density of dural lymphatics was higher around the venous sinuses than in more lateral areas of the dura, and higher within the meningeal layer than the periosteal layer of the dura. As expected, red blood cells were not seen within lymphatics. In marmosets, direct comparison between in vivo MRI and histopathology was performed ([@bib1]; [@bib8]; [@bib19]). As shown in [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, the three dural vessels detected on coronal postcontrast T2-FLAIR and on subtraction images colocalize with three clusters of dural cells expressing the full panel of lymphatic endothelial markers (LYVE-1, D2-40 podoplanin, PROX1, COUP-TFII) and CCL21, a chemokine implicated in lymphatic transmigration.

In the ongoing debate about the precise localization of lymphatics within the meninges (either completely within the dura or 'shared' between the dura and the arachnoid) ([@bib13]; [@bib25]), our pathological data clearly show that at least some lymphatics are contained entirely within the dura ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). On limited evaluation, we were unable to visualize lymphatics within the leptomeninges, but additional dedicated studies, ideally with nonconventional tissue-preparation methods, are warranted to fully explore this possibility. A comprehensive map of the meningeal lymphatic network would have implications for unraveling the ways in which the meningeal lymphatics participate in waste clearance and in immune cell trafficking within the central nervous system ([@bib16]; [@bib13]; [@bib25]).

In inflammatory pathological conditions, cellular migration toward the dural lymphatics might be profoundly enhanced by specific signaling and lymphatic plasticity ([@bib3]; [@bib12]; [@bib30]). Noteworthy in this context are clusters of extravascular CD3+ lymphocytes and CD68+ phagocytic meningeal macrophages that we observed in the dura of several multiple sclerosis autopsies (not shown), confirming intense immune cell trafficking and communication. Indeed, without proper normative comparison, we cannot rule out that the extensive presence of small lymphatics observed in multiple sclerosis dura samples is the result of inflammation-mediated lymphoangiogenesis. On the other hand, lymphatic dysfunction might impair waste clearance in neurodegenerative diseases and aging, in line with the recently captured deposition of β-amyloid in human dura in elderly people ([@bib14]).

Differently from experiments implementing injections of tracers within brain structures, here we aimed primarily to image dural lymphatic vessels in human and nonhuman primates, but we could not prove whether dural lymphatic vessels drain immune cells, CSF, or other substances from the brain to deep cervical lymph nodes, nor could we assess any link with the glymphatic system ([@bib9]; [@bib32]; [@bib10]). Such an analysis would probably require injection of specific MRI-detectable tracers and acquisition of MRI time-series (not thoroughly explored in the current work), an important future research direction for the nonhuman primate work.

Overall, our data clearly and consistently demonstrate the existence of lymphatic vessels within the dura mater of human and nonhuman primates. Together with recent studies in rodents, our results show that the meningeal lymphatic system is evolutionarily conserved in mammals and confirm, after exactly two centuries, what the Italian anatomist Paolo Mascagni speculated were lymphatic vessels at the surface of human brain ([@bib22]). The ability to image the meningeal lymphatics noninvasively immediately suggests the possibility of studying potential abnormalities in human neurological disorders.

Materials and methods {#s3}
=====================

Approvals {#s3-1}
---------

We carried out human studies under a protocol ([NCT02504840]{.ul}) approved by NIH Institutional Review Board. Informed consent was obtained from all participants. Formalin-fixed human brains were attained at autopsy after obtaining consent from the next of kin. Animal studies were performed under a protocol approved by the Institutional Animal Care and Use Committee.

Human imaging {#s3-2}
-------------

We studied five healthy volunteers (three women, age range 28--53 years) and obtained scans on a 3-tesla MRI unit (Skyra, Siemens Healthcare, Erlangen, Germany), using the body coil for radiofrequency transmission and a 32-element phased array coil for reception.

Prior to injection of gadolinium-based contrast agent, the following high-resolution MRI sequences were collected:

1.  Whole-brain T1-Magnetization Prepared Rapid Acquisition of Gradient Echoes (MPRAGE, sagittal 3D turbo-fast low angle shot \[TFL\] sequence, acquisition matrix 256 × 256, isotropic resolution 1 mm, 176 slices, repetition time \[TR\]/echo time \[TE\]/inversion time \[TI\]=3000/3/900 ms, flip angle 9, acquisition time 5 min 38 s);

2.  Limited T2-weighted Fluid Attenuation Inversion Recovery (FLAIR, coronal 2D acquisition over the superior sagittal sinus, field-of-view 256 × 256, 22 slices, reconstructed in-plane resolution 0.25 mm x 0.25 mm, 42 contiguous 3 mm slices, TR/TE/TI = 6500/93/2100 ms, echo train length 17, bandwidth 80 Hz/pixel, acquisition time 5 min), optimized for detection of gadolinium-based contrast agent in the subarachnoid space ([@bib2]);

3.  Black-blood scan (coronal 2D acquisition, Sampling Perfection with Application optimized Contrasts using different flip angle Evolution \[SPACE\] sequence, field-of-view 174 × 174, matrix 320 × 320, reconstructed in-plane resolution 0.27 × 0.27 mm, 64 contiguous 0.5 mm sections, TR/TE = 938/22 ms, echo train length 35, bandwidth 434 Hz/pixel, acquisition time 7 min 50 s). A series of 2 or three overlapping coronal acquisitions were acquired to cover most of the cerebral hemispheres;

4.  Whole-brain T2-FLAIR scan (coronal 3D acquisition, SPACE sequence, field-of-view 235 × 235, matrix 512 × 512, reconstructed in-plane resolution 0.46 × 0.46 mm, 176 1 mm sections, TR/TE/TI = 4800/354/1800 ms, nonselective inversion pulse, echo-train length 298, bandwidth 780 Hz/pixel, acceleration factor 2, acquisition time 14 min);

5.  Whole-brain T1-SPACE (axial 3D acquisition, acquisition matrix 256 × 256, isotropic resolution 0.9 mm, 112 sections, TR/TE = 600/20 ms, flip angle 120, echo-train length 28, acquisition time 10 min).

We repeated these acquisitions after injection of gadobutrol (Gadavist, Bayer HealthCare, Whippany, NJ) in all five participants. In 2 of the participants, we also repeated the entire protocol prior to and following intravenous injection of gadofosveset ([@bib15]) (Ablavar, Lantheus Medical Imaging, N Billerica, MA). Injections followed the manufacturer's suggested dosing (0.1 mmol/kg for gadobutrol, 0.03 mmol/kg for gadofosveset).

Marmoset imaging {#s3-3}
----------------

We studied three healthy adult common marmosets (*Callithrix jacchus*) (one female, two males, age range 4--11 years). After the baseline MRI, experimental autoimmune encephalomyelitis (EAE) was induced in 2 marmosets with 0.2 mg of fresh-frozen human white matter homogenate as previously described ([@bib7]). Marmosets were placed in a sphinx position within the magnet, and scans were obtained on a 7-tesla MRI unit (Avance AVIII, Bruker BioSpin, Billerica, MA, USA). Data acquisition was performed in transmit-only/receive-only mode using a homemade linear birdcage coil (120 mm inner diameter) as a radiofrequency transmitter and a homemade, 8-channel radio-frequency surface-array receiver coil assembly placed over the head of the animal. Prior to injection of contrast agent, we collected:

1.  Whole-brain T1-weighted MPRAGE scan (coronal 3D acquisition, Modified Driven Equilibrium Fourier Transform \[MDEFT\] sequence, in-plane voxel size 0.15 mm x 0.15 mm, 36 contiguous 1 mm sections, TR/TE/TI = 12.5/4/1200 ms, flip angle 12 degrees, 2 segments of 1800 ms, acquisition time 7 min);

2.  Whole-brain T2-FLAIR scan (coronal 2D acquisition, Rapid Acquisition with Relaxation Enhancement \[RARE\] sequence, voxel size 0.15 mm x 0.15 mm, 36 contiguous 1 mm sections, TR/TE/TI = 10,000/36/2500 ms, flip angle 90--180 degrees, 2 averages, acquisition time 13 min).

We performed the same scans following intravenous injection of gadobutrol and gadofosveset, in two different MRI sessions. Injections used single (0.1 mmol/kg for gadobutrol, 0.03 mmol/kg for gadofosveset) or triple the recommended human dosing (0.3 mmol/kg for gadobutrol, 0.09 mmol/kg for gadofosveset).

Image processing {#s3-4}
----------------

Scanner-generated DICOM images were converted into NIFTI files for postprocessing. Using MIPAV software (<https://mipav.cit.nih.gov>), precontrast scans were rigidly registered to postcontrast scans, and subtraction images were created for anatomical identification of dural lymphatic vessels. 3D skull-stripped subtraction images were then imported into Osirix software for maximum intensity projection (MIP) 3D rendering. The same postprocessing was performed for scans acquired after gadofosveset injection, and a direct comparison between the two gadolinium-based contrast agents was made.

Neuropathological evaluation of human and primate dural lymphatic vessels {#s3-5}
-------------------------------------------------------------------------

Neuropathological evaluation focused on human and marmoset brain dura mater samples. Multiple human dura samples were obtained from 2 formalin-fixed brains (60- and 77-year-olds with longstanding progressive multiple sclerosis) and from a 33-year-old with refractory epilepsy undergoing anterior temporal lobectomy ([Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Primate samples were obtained from 3 adult common marmosets (2 with EAE) \[[Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}\]. After general anesthesia and transcardial perfusion of 4% paraformaldehyde, marmoset brains were extracted and stored in 10% formalin. For primate brains, MRI-matched histological sections were achieved via 7T MRI of the fixed brain and subsequent gross sectioning with an individualized, MRI-designed, 3D-printed cutting box, as previously described ([@bib1]; [@bib8]; [@bib19]).

Coronal and longitudinal 3 to 7 μm paraffin sections of the dura mater were stained with hematoxylin and eosin (H and E). Immunohistochemical and immunofluorescent analysis for classical lymphatic endothelial cell markers \[lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), podoplanin (D2-40), prospero homeobox protein 1 (PROX1), COUP transcription factor 2 (COUP-TFII) and CCL21\], were performed on representative slides. Selective double staining for lymphatic *vs.* vascular endothelial markers (D2-40/CD31 and PROX1/CD31) were also executed on representative sections and implemented for histological quantification; the maximum diameter was recorded for each lymphatic vessel, and descriptive statistics were computed. We also stained for lymphocytes (CD3) and monocytes/macrophages (CD68). Five-μm paraffin sections of the human skin were used as positive controls for lymphatic endothelium cell marker assessment ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). For comparison, 10 paraffin human brain tissue blocks, selected for the presence of nearly intact leptomeningeal architecture, were implemented to assess the presence of lymphatics within the subarachnoid space and cerebral parenchyma.

Antibodies {#s3-6}
----------

Source, antibody type, and dilution are indicated sequentially as follows: LIVE-1 (Abcam, UK, rabbit polyclonal, 1:200); podoplanin D2-40 (AbD Serotec, Hercules, CA, mouse monoclonal, 1:50); PROX-1 (AngioBio, San Diego, CA, rabbit polyclonal, 1:50); COUP TFII (R&D Systems, Minneapolis, MN, mouse monoclonal, 1:200); CCL21 (Abcam, rabbit polyclonal, 1:200); CD31 (Abcam, rabbit polyclonal, 1:50); CD68 KP1 (Thermofisher, Waltham, MA, mouse monoclonal, 1:100); CD3 (Dako, Santa Clara, CA, rabbit polyclonal, 1:200); goat anti-mouse Alexafluor 488 IgG (Invitrogen, Carlsbad, CA, 1:250) and goat anti-rabbit Alexafluor 594 IgG antibodies (Invitrogen, 1:250).

Immunohistochemistry {#s3-7}
--------------------

Immunostaining was performed on 3 to 7 μm-thick consecutive paraffin sections with antibodies to LYVE1, D2-40 podoplanin, PROX1, COUP-TFII, CCL21, CD31, CD68, CD3 and visualized with 3,3\'-diaminobenzidine (DAB). Briefly, after deparaffinization, sections were rinsed in triphosphate-buffered saline (TBS) for 10 min each, processed for antigen retrieval, and treated in 3% hydrogen peroxide for 10 min. Sections were blocked with a protein-blocking solution for 20 min and incubated with the primary antibodies overnight at 4°C or 1 hr at room temperature, then rinsed and incubated with secondary antibodies for 30 min. The immunoreaction was visualized with DAB. After washing, sections were counterstained with 10% hematoxylin. Stained sections were visualized and digitized (Axio Observer Z.1, Carl Zeiss Microscopy, NY, USA). Selective double staining for lymphatic and vascular endothelium markers (D2-40 podoplanin/CD31, PROX1/CD31), as well double staining for D2-40 podoplanin/PROX1,were also executed on representative sections. Double staining was performed using, in sequence, DAB horseradish peroxidase (HRP) and Vector Blue alkaline phosphatase (AP) methods. As negative control, sections of human skin, human dura mater, and marmoset brain were stained without the primary antibodies; no background staining and/or nonspecific binding was noted ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

Immunofluorescence {#s3-8}
------------------

After deparaffinization, sections were treated using the same method as described above. Sections were incubated with a cocktail of antibodies to D2-40 podoplanin and CD31 for 2 hr at room temperature, then rinsed and incubated with secondary antibodies with Alexafluor 488 goat anti-mouse (Invitrogen, dilution 1:250) and Alexafluor 594 goat anti rabbit IgG antibodies (Invitrogen, dilution 1:250), respectively, for 30 min at room temperature. After washing, sections were mounted with DAPI Immuno Mount. Stained sections were visualized and digitized (Axio Observer Z.1, Carl Zeiss Microscopy, NY, USA).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and David Van Essen as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This report is a follow-up on the recent publications on the meningeal lymphatic vessels in rodents. They study image human and nonhuman primates using T2-FLAIR and T1-weighted imaging in combination with systemic administration of contrast agents. The analysis shows that the meningeal lymphatic vessels in human and nonhuman primate meninges are very similar to those described in rodents.

Essential revisions:

1\) In this study, and in the previous work on the glymphatic system, there is little or no mention of the well-known Virchow-Robin perivascular spaces, easily observable using high resolution MRI (e.g. Thomas et al., MRM 2004). Because these features of brain anatomy are well known, having been studied for over a century, and they are also observable with MRI, it is quite surprising that they were not mentioned in the present manuscript. Were they not observed at all? If indeed they comprise a part of the lymphatic circulation, one would expect them to appear with significant contrast in the gadobutrol labelled images. The authors could provide additional visualisation.

2\) Lymphatic flow. One of the criticisms of the \'glymphatic system\' concept concerns the shortage of evidence that the lymph has a directional flow within it. A study of the kind described in this manuscript could help to rectify this lack -- if a time series of images were obtained, displaying successive enhancement of lymphatic channels in the order predicted by the theory. The authors might want to comment on this possibility.

3\) The MRI imaging is based on the use of two gadolinium-based tracers, one (gadofosveset) which is confined to the blood by binding to serum albumin, and one (gadobutrol) which can exit through blood vessel walls and pass into the lymph vessels. The latter showed accumulation in (putative) lymph vessels in the dura, while the former did not. This is encouraging but there are the following problems:

a\) The putative lymphatics are barely visible, especially in the subtraction images in [Figure 2](#fig2){ref-type="fig"}. The authors should increase the intensity and the contrast of the images (taking care to specify what manipulations have been done in the figure legend) -- for example, pasting [Figure 2](#fig2){ref-type="fig"}\'s subtraction images into Powerpoint and increasing both the intensity and contrast by 40% leads to much more easily visible lymphatics. A similar process should be applied to [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for the subtraction images, if the authors wish to convince the reader that there are no lymphatics visible with gadofosveset.

b\) The videos show the extent of the lymphatics far more impressively than do the coronal sections in [Figures 1](#fig1){ref-type="fig"} and 2. Panels should be added to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} showing sagittal sections or simply a picture of the 3D rendering in the videos. The contrast should also be increased in the videos.

4\) Ultimately the MRI data need validating by immunocytochemistry with lymphatic specific markers, and this is attempted in [Figures 3](#fig3){ref-type="fig"} and 4. Again there are problems:

a\) [Figure 3](#fig3){ref-type="fig"} is very poorly presented for readers not familiar with the detailed anatomy. I cannot understand what [Figure 3B](#fig3){ref-type="fig"} shows; add some explanatory labels. For panels D-E we need some clue as to exactly where in the brain the tissue is located -- show a picture like that in [Figure 4A](#fig4){ref-type="fig"}, with rectangles to approximately locate the images presented in D-E. No scale bar size is stated for panels D and E and K.

b\) In humans, Prox 1 or podoplanin (brown) are used as a lymphatic marker and CD31 (blue) as an endothelial marker. Unfortunately the images in panels 3D-E are so faint that colors are not visible (in contrast the immunofluorescence in panels J-K is much clearer). In the magnified panels colors are visible but the background labeling is high. Any dark brown label is attributed to the presence of lymphatics (e.g. there are 5 structures annotated LV in panel F) yet it is unclear how these vessels relate to those seen in the MRI pictures, where there are 3 lymph vessels in [Figure 1](#fig1){ref-type="fig"}. Were the IHC and the MRI done on the same brains? If so, is it not possible to state whether the number of lymph vessels found by MRI is the same as is found by IHC? The fact that the IHC finds more vessels (below the resolution of MRI?) at least needs to be discussed. Also, the fact that podoplanin is in cells other than lymph vessels should be mentioned (e.g. kidney podocytes and possibly capillary pericytes, which could confound the interpretation: https://www.ncbi.nlm.nih.gov/pubmed/25908104).

c\) For the marmoset data, the text states that the number of lymphatics seen with MRI was the same as with IHC, yet the number of lymphatics seen in [Figure 4A](#fig4){ref-type="fig"} could be 2 or 3 (enhance the intensity and contrast, and label them with red arrows), while in [Figure 4C](#fig4){ref-type="fig"} It is unclear exactly which brownish structures are being defined as lymphatics -- they need explaining better, e.g. by drawing a dashed red line round them.

d\) For both human and marmoset tissue, it is essential to show the (hopefully absent) labeling when the primary antibody for PROX1 or D2-40 is omitted from the IHC. Ideally this should be in brain, but skin would be an acceptable substitute if brain is unfeasible.

e\) [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} and its associated text is fairly peripheral to the main point of this paper -- it might be better in a separate paper combined with more rigorous data showing lymphatic trafficking of immune cells.

10.7554/eLife.29738.018

Author response

> Essential revisions:
>
> 1\) In this study, and in the previous work on the glymphatic system, there is little or no mention of the well-known Virchow-Robin perivascular spaces, easily observable using high resolution MRI (e.g. Thomas et al., MRM 2004). Because these features of brain anatomy are well known, having been studied for over a century, and they are also observable with MRI, it is quite surprising that they were not mentioned in the present manuscript. Were they not observed at all? If indeed they comprise a part of the lymphatic circulation, one would expect them to appear with significant contrast in the gadobutrol labelled images. The authors could provide additional visualisation.

We thank the reviewers for raising this point. We were able to image the meningeal lymphatic vessels because there is no blood-meningeal barrier in the dura mater; hence, gadolinium contrast can quickly extravasate into the connective tissue, from where it collects into the lymphatic vessels. On the other hand, the Virchow-Robin perivascular spaces in the brain parenchyma, which (as the reviewer correctly points out) are commonly seen on conventional clinical MRI scans, are known not to enhance after intravenously injected gadolinium contrast. This is most likely related to the presence of an intact blood-brain barrier which, under physiological conditions, is not permeable to contrast agents. In this context, we note that our approach does not address the recently described "glymphatic" system, which may comprise the Virchow-Robin spaces, the noninvasive imaging of which would require an altogether different approach from what we have presented in this paper. These points have been better clarified in the manuscript (1^st^ paragraph of the Results/Discussion section).

> 2\) Lymphatic flow. One of the criticisms of the \'glymphatic system\' concept concerns the shortage of evidence that the lymph has a directional flow within it. A study of the kind described in this manuscript could help to rectify this lack -- if a time series of images were obtained, displaying successive enhancement of lymphatic channels in the order predicted by the theory. The authors might want to comment on this possibility.

We thank the reviewers for this comment as well. As mentioned in the reply to point 1, imaging the glymphatic system would require a different approach from the one we have presented. Indeed, even though we collected time series images throughout the first hour after injection of contrast agent (an example of which is shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), we did not observe clear dynamic changes (e.g. flow) in the imaging characteristics of the meningeal vessels. More subtle dynamic changes might have been observed had we done more frequent temporal sampling, however the requirement for extremely high spatial resolution to visualize the meningeal lymphatic vessels made this impossible. We have now included a comment in the Discussion.

> 3\) The MRI imaging is based on the use of two gadolinium-based tracers, one (gadofosveset) which is confined to the blood by binding to serum albumin, and one (gadobutrol) which can exit through blood vessel walls and pass into the lymph vessels. The latter showed accumulation in (putative) lymph vessels in the dura, while the former did not. This is encouraging but there are the following problems:
>
> a\) The putative lymphatics are barely visible, especially in the subtraction images in [Figure 2](#fig2){ref-type="fig"}. The authors should increase the intensity and the contrast of the images (taking care to specify what manipulations have been done in the figure legend) -- for example, pasting [Figure 2](#fig2){ref-type="fig"}\'s subtraction images into Powerpoint and increasing both the intensity and contrast by 40% leads to much more easily visible lymphatics. A similar process should be applied to [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} for the subtraction images, if the authors wish to convince the reader that there are no lymphatics visible with gadofosveset.

We thank the reviewers for this recommendation. The figures have been modified accordingly.

> b\) The videos show the extent of the lymphatics far more impressively than do the coronal sections in [Figures 1](#fig1){ref-type="fig"} and 2. Panels should be added to [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} showing sagittal sections or simply a picture of the 3D rendering in the videos. The contrast should also be increased in the videos.

We added a new figure ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) including static snapshots of the 3D rendering of the putative human dural lymphatics and anatomical labels for ease of interpretation, as suggested by the reviewers.

> 4\) Ultimately the MRI data need validating by immunocytochemistry with lymphatic specific markers, and this is attempted in [Figures 3](#fig3){ref-type="fig"} and 4. Again there are problems:
>
> a\) [Figure 3](#fig3){ref-type="fig"} is very poorly presented for readers not familiar with the detailed anatomy. I cannot understand what [Figure 3B](#fig3){ref-type="fig"} shows; add some explanatory labels. For panels D-E we need some clue as to exactly where in the brain the tissue is located -- show a picture like that in [Figure 4A](#fig4){ref-type="fig"}, with rectangles to approximately locate the images presented in D-E. No scale bar size is stated for panels D and E and K.

We thank the reviewers for this recommendation and apologize that the first version was difficult to decipher. These figures have been modified accordingly.

> b\) In humans, Prox 1 or podoplanin (brown) are used as a lymphatic marker and CD31 (blue) as an endothelial marker. Unfortunately the images in panels 3D-E are so faint that colors are not visible (in contrast the immunofluorescence in panels J-K is much clearer). In the magnified panels colors are visible but the background labeling is high. Any dark brown label is attributed to the presence of lymphatics (e.g. there are 5 structures annotated LV in panel F) yet it is unclear how these vessels relate to those seen in the MRI pictures, where there are 3 lymph vessels in [Figure 1](#fig1){ref-type="fig"}. Were the IHC and the MRI done on the same brains? If so, is it not possible to state whether the number of lymph vessels found by MRI is the same as is found by IHC? The fact that the IHC finds more vessels (below the resolution of MRI?) at least needs to be discussed. Also, the fact that podoplanin is in cells other than lymph vessels should be mentioned (e.g. kidney podocytes and possibly capillary pericytes, which could confound the interpretation: <https://www.ncbi.nlm.nih.gov/pubmed/25908104>).

The Discussion (Results/Discussion 3^rd^ paragraph) addresses differences in the number of lymphatics seen on MRI vs. histopathology, as follows: "It is worth noting that the lymphatics visualized by MRI are large slow-flow lymphatic ducts, whereas blind-ending and small lymphatic capillaries, clearly seen by histopathology ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), are unlikely to be revealed by MRI."

We agree that lymphatic immunohistochemical markers are not totally specific for lymphatic vessels (please see Results/Discussion 4^th^ paragraph), which is the reason we needed to test several of them (LYVE-1, podoplanin D2-40, PROX1, COUP-TFII, and CCL21) and to compare results on consecutive sections of dura mater. The suggested reference has been now added to the manuscript.

For the humans, the imaging and histopathology have been performed, of necessity, in different people (please see [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"} for human tissue sampling), as described in the Materials and methods section. On the animal side, we studied a total of 5 marmosets for this study: 2 of which were used exclusively for MRI-histopathological correlations (please see [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), 2 for gabobutrol vs. gadofosvet MRI in vivo experiments, and 1 for both the gabobutrol vs. gadofosvet MRI in vivo experiments and the histopathological characterization.

The relevant figure and legends have been modified according to the request of the reviewers.

> c\) For the marmoset data, the text states that the number of lymphatics seen with MRI was the same as with IHC, yet the number of lymphatics seen in [Figure 4A](#fig4){ref-type="fig"} could be 2 or 3 (enhance the intensity and contrast, and label them with red arrows), while in [Figure 4C](#fig4){ref-type="fig"} It is unclear exactly which brownish structures are being defined as lymphatics -- they need explaining better, e.g. by drawing a dashed red line round them.

We apologize for any confusion. For the marmoset data, we stated in the text that the 3 areas enhancing on MRI correspond to clusters of cells positive for lymphatic markers (4^th^ paragraph of the Results/Discussion section). Unfortunately, it was not always straightforward to recognize the vessel-like structures, likely due to the fragility of the dura mater after preparation and immunohistochemical processing. The figure and the legend have been modified according to the request of the reviewers.

> d\) For both human and marmoset tissue, it is essential to show the (hopefully absent) labeling when the primary antibody for PROX1 or D2-40 is omitted from the IHC. Ideally this should be in brain, but skin would be an acceptable substitute if brain is unfeasible.

We have performed negative control staining in human dura and skin as well as in marmoset brain. We included them in Figure 3---figure supplement 3. They show no background staining and/or nonspecific binding. An additional sentence has been added to the Materials and methods section.

> e\) [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} and its associated text is fairly peripheral to the main point of this paper -- it might be better in a separate paper combined with more rigorous data showing lymphatic trafficking of immune cells.

The figure has been deleted accordingly.

[^1]: These authors contributed equally to this work.
